Syntano Technology Venture

Syntano is a biotechnology company specializing in the development of synthetic carbohydrate-based vaccines to combat antimicrobial-resistant (AMR) bacterial infections. Spun out from the Max Planck Institute of Colloids and Interfaces, the company leverages a proprietary automated glycan assembly (AGA) platform to create precise, well-defined synthetic antigens. Their lead programs target high-priority pathogens such as Klebsiella pneumoniae and Streptococcus pneumoniae, which are major causes of hospital-acquired infections. By utilizing synthetic glycans rather than extracted polysaccharides, Syntano aims to overcome the limitations of traditional conjugate vaccines, offering improved purity, scalability, and broader protection. The company is positioned at the intersection of synthetic chemistry and immunology to address critical gaps in the global infectious disease landscape.